APG Asset Management N.V. Has $40.56 Million Stock Position in Zoetis Inc. $ZTS

Key Points

• APG Asset Management N.V. has reduced its stake in Zoetis Inc. by 3.6%, owning 266,102 shares valued at $40.56 million after selling 9,861 shares during the first quarter.
• Several research firms have downgraded Zoetis's stock ratings, with Stifel Nicolaus reducing the rating from "buy" to "hold" and lowering the price target to $160.00.
• During its latest earnings report, Zoetis reported earnings of $1.76 per share, exceeding analysts' expectations, alongside a revenue of $2.46 billion for the quarter.

APG Asset Management N.V. reduced its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 3.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 266,102 shares of the company's stock after selling 9,861 shares during the period. APG Asset Management N.V. owned 0.06% of Zoetis worth $40,561,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Coppell Advisory Solutions LLC increased its holdings in shares of Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after purchasing an additional 64 shares during the last quarter. Lindbrook Capital LLC increased its holdings in shares of Zoetis by 1.8% in the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after purchasing an additional 65 shares during the last quarter. Quotient Wealth Partners LLC increased its holdings in shares of Zoetis by 2.3% in the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after purchasing an additional 72 shares during the last quarter. Broadway Wealth Solutions Inc. increased its holdings in shares of Zoetis by 4.4% in the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after purchasing an additional 73 shares during the last quarter. Finally, Menard Financial Group LLC increased its holdings in shares of Zoetis by 3.8% in the first quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock valued at $305,000 after purchasing an additional 75 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZTS. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. UBS Group dropped their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Finally, Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.18% of the stock is currently owned by company insiders.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $156.3180 on Friday. The firm has a market cap of $69.28 billion, a PE ratio of 26.91, a PEG ratio of 2.51 and a beta of 0.88. The company's 50 day moving average price is $153.84 and its two-hundred day moving average price is $158.52. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.